Life Sciences

GSK warned about misleading TV ad

Pharma Compliance Alert, March 11, 2009

A direct-to-consumer television ad misbrands GlaxoSmithKline’s prostate drug Avodart, according to an FDA warning letter.

The 60-second ad presents misleading comparative claims and overstates the efficacy of Avodart. Specifically, the ad claims Avodart is the only medication that shirks the prostate. Merck’s Proscar also reduces the size of the prostate and has a similar indication. Visual effects in the ad also exaggerate Avodart’s effectiveness, according to the FDA.

Most Popular

Related Articles